Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, September 26, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) confirms the U.S. District Court for the District of Delaware’s order granting an interim injunction enjoining Hospira from launching its generic version of LEXISCAN® until October 5, 2022. The District Court, however, denied Astellas’ request for a Preliminary Injunction while Astellas’ appeal is pending with the Court of Appeals for the Federal Circuit (CAFC). Astellas is filing a Motion for Preliminary Injunction with the CAFC to prevent Hospira from launching generic LEXISCAN® until the CAFC resolves Astellas’ pending appeal of the district court decision.
On May 19, 2022, the U.S. District Court for the District of Delaware issued its decision that all of the asserted claims of the 8,106,183; 8, 524,883; and RE47301 patents for LEXISCAN® (regadenoson injection) 0.4 mg/mL are not infringed. The patent infringement trial involved one Abbreviated New Drug Application (ANDA) filer, Hospira, Inc. Astellas appealed this decision with the CAFC on June 1, 2022.
Astellas is reviewing the potential financial impacts of this district court decision for the fiscal year ending March 31, 2023.
Click below for a copy of the full press release
Follow us
